Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection
Plus: Pfizer CEO Relaxed About Vaccine Logistics
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
You may also be interested in...
The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.
The UK's MHRA has granted an emergency authorization to the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.